Confusion Persists Around the Interchangeability Designation for Biosimilars
Pharmacy Times,
With numerous adalimumab biosimilars launching in the United States in 2023, the impact of an FDA interchangeability…
With numerous adalimumab biosimilars launching in the United States in 2023, the impact of an FDA interchangeability…
With numerous adalimumab biosimilars launching in the US in 2023, the impact of an FDA interchangeability designation has been…
When AbbVie’s blockbuster rheumatoid arthritis drug finally sees some competition in the US in 2023, there’s likely to be a…